Affordable Access

Access to the full text

Ibrutinib in primary central nervous system diffuse large B-cell lymphoma

Authors
  • T Low, Justin1
  • B Peters, Katherine1, 2
  • 1 Department of Neurosurgery, The Preston Robert Tisch Brain Tumor Center, Duke Cancer Institute, Duke University Medical Center, Durham, NC 27710, USA
  • 2 Department of Neurology, The Preston Robert Tisch Brain Tumor Center, Duke Cancer Institute, Duke University Medical Center, Durham, NC 27710, USA
Type
Published Article
Journal
CNS Oncology
Publisher
Future Medicine
Publication Date
Mar 06, 2020
Volume
9
Issue
1
Identifiers
DOI: 10.2217/cns-2019-0022
PMID: 32141313
PMCID: PMC7163401
Source
PubMed Central
Keywords
License
Green

Abstract

The standard regimen for the treatment of newly diagnosed primary CNS lymphoma (PCNSL) remains regimens that contain high-dose methotrexate (MTX). While these regimens can provide control for some patients, there is a dearth of options for the treatment of patients with PCNSL who cannot tolerate MTX-containing regimens, or whose cancers are refractory to MTX. In this article, we review a promising new option; ibrutinib, a Bruton tyrosine kinase inhibitor, for patients with relapsed and refractory PCNSL.

Report this publication

Statistics

Seen <100 times